On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax COVID-19 vaccine.

Novavax and Canada were expected to finalize an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as the second quarter of 2021. This purchase arrangement was subject to licensure of the Novavax vaccine by Health Canada.